Homocystinuria (HCU)
11 Sept 2026 路 4 min read

On this page9 sections
Homocystinuria (HCU) is a rare but potentially serious inherited metabolic disorder. In a healthy body, dietary protein is broken down into smaller building blocks called amino acids, which are then processed by specialized chemicals known as enzymes.
Individuals with HCU lack a functional enzyme needed to properly metabolize the amino acid methionine. This deficiency triggers a toxic accumulation of both methionine and another amino acid called homocysteine in the blood. If left untreated, this chemical buildup causes severe damage to the eyes, brain, skeletal system, and vascular pathways.
1. Newborn Screening Protocol
In Ireland, infants are proactively screened for HCU via the standard heel prick screening (Newborn Bloodspot Screening). This test is offered to all parents when their baby is between 3 and 5 days old.
If the screen returns a positive result for HCU, the infant is referred immediately to the National Centre for Inherited Metabolic Disorders (NCIMD) at Children's Health Ireland (CHI) at Temple Street, Dublin. The child will be placed under the lifelong care of a specialist metabolic team, including a metabolic consultant, specialized nurses, and a metabolic dietitian.
2. Emerging Symptoms of Unmanaged HCU
HCU is typically asymptomatic during the first year of life. However, if it is not caught early or managed correctly, severe and irreversible clinical symptoms will manifest as the child grows:
Vision Impairment: Dislocation of the eye lenses and severe short-sightedness (myopia).
Skeletal Complications: Abnormally weak, brittle bones (osteoporosis) alongside joint deformities.
Vascular Events: A drastically elevated risk of developing dangerous blood clots and experiencing premature strokes.
Neurological Damage: Structural brain damage that causes significant developmental delays and cognitive impairment.
3. Lifelong Management and Treatment Pathways
While there is no cure for HCU, early intervention allows most children to live long, healthy lives. Treatment must be maintained for the rest of the patient's life and centers on three primary approaches:
High-Dose Vitamin B6 (Pyridoxine)
A subset of infants with HCU respond positively to high doses of Vitamin B6. This vitamin helps activate residual enzyme function, successfully lowering homocysteine levels in the blood. Patients who are responsive will take daily, high-dose Vitamin B6 supplements permanently.
Specialized Low-Protein Diet
Infants who do not respond to Vitamin B6 must be transitioned onto a strict, low-protein medical diet to keep incoming methionine levels as low as possible.
Dietary Precision: Because growing children still require a baseline amount of protein for healthy physical development, a metabolic dietitian will teach you how to precisely measure and restrict breast milk or standard infant formula.
Medical Formulas: Infants are prescribed a specialized HCU infant formula. This customized product is completely methionine-free but packed with all the alternative amino acids, vitamins, and essential minerals your baby needs to thrive.
Lifelong Adherence: As children transition into adulthood, they must learn to strictly audit their food intake and maintain continuous contact with their metabolic clinic for routine monitoring.
Prescribed Medication
Patients may be prescribed a specialized medication called betaine. This drug works through an alternative metabolic pathway, actively converting excess homocysteine back into safer compounds and clearing it from the bloodstream.
Routine Laboratory Blood Tests
Patients require regular, lifelong blood draws. These routine laboratory checks monitor the exact concentration of homocysteine in the bloodstream, allowing the metabolic team to adjust medication dosages and dietary targets instantly.
4. Genetic Inheritance Pattern
HCU is an autosomal recessive condition caused by an altered or faulty gene. Parents are typically unaffected "carriers" who possess only a single copy of the mutated gene and display no symptoms themselves.
If two carriers conceive a child, the statistical probabilities for each pregnancy are calculated as follows:
1 in 4 (25%) chance that the child inherits a faulty gene from both parents and develops HCU.
1 in 2 (50%) chance that the child inherits one faulty gene and one normal gene, becoming an asymptomatic carrier like their parents.
1 in 4 (25%) chance that the child inherits a pair of completely normal genes, remaining entirely unaffected and non-carriers.
Disclaimer
The information provided here is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional or your GP for specific medical concerns, diagnoses, or health advice. Never disregard professional medical advice or delay seeking it because of information you have read here.
